Table 11_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 13_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 9_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 4_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 7_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 3_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 8_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 12_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Table 5_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx by Ling-zhi Yang (20418434)

“…</p>Finding<p>In 2021, there were 24,220,856 (95% UI: 18,476,943–30,677,995) patients with epilepsy, with an age-standardized prevalence rate (ASPR) of 307.38 per 100,000 persons (95% UI: 234.71–389.02) and an age-standardized incidence rate (ASIR) of 42.821 per 100,000 persons (95% UI: 31.24–53.72).The global age-standardized mortality rate (ASMR) of epilepsy was 1.74 per 100,000 population (95% UI: 1.46–1.92); The age-standardized DALYs rate (ASDR) were 177.85 per 100,000 population (95% UI: 137.66–225.90); 154.25 per 100,000 population for females [114.73–201.76], and 201.29 per 100,000 population for males [157.93–252.74]. …”

Descriptive and inferential analysis. by Júlio A. Costa (13172340)

“…They were similar in age (61.6 ± 8.6 and 60.8 ± 6.9, respectively). Males covered a higher distance per minute than females, with sex showing a moderate effect (63.3 ± 10.7 m/min vs. 54.7 ± 15.8 m/min; p < .001; Cohen’s <i>d</i>_{<i>unbiased</i>} = 0.69 [0.36; 1.03]), especially in fast walking (41.7 ± 12.2 m/min vs. 32.6 ± 16.7 m/min; p < .001; Cohen’s <i>d</i>_{<i>unbiased</i>} = 0.66 [0.33; 1.00]). …”

Regulation of the E(spl)-C and <i>invected-engrailed</i> complex by cohesin and Nipped-B. by Cheri A. Schaaf (144616)

“…Nipped-B knockdown shows similar time courses in Nipped-B protein and E(spl)-C and <i>invected-engrailed</i> transcripts (not shown), except that some E(spl)-C transcripts decrease on day 3 (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0006202#pone-0006202-g003" target="_blank">Figure 3</a>). …”

Data Sheet 1_Plasma testosterone concentration is correlated with circulating immune cell abundance in transgender young people on gender-affirming hormone treatment.pdf by Alice A. White (21695726)

“…Differences in the abundance of other T cell subsets were detected in both trans males and trans females, however only a decrease in CD161⁺ T effector memory cells in trans males, compared to control females, was associated with lower testosterone levels. …”

Data_Sheet_1_The global, regional, and national burden of stomach cancer among adolescents and young adults in 204 countries and territories, 1990–2019: A population-based study.ZI... by Ziqiang Zhang (7137512)

“…Compared with 1990, in 2019 more than 1,075 more incident cases of AYA stomach cancer were estimated with a decrease of 7,784 deaths. Despite the increase in absolute number of incident cases, the worldwide age-standardized rates of AYA stomach cancer (incidence, deaths, and DALYs) have declined since 1990. …”

The Ipsilateral Retinogeniculate Projection Is Altered in Ten_m3 KO Mice by Catherine A Leamey (62507)

“…In WTs, a smooth bell-shaped curve is seen that rises to peak around 30%–40% of the DV-ML axis and decreases to low values by around 60% of the axis. …”

Effect of Integrated Capacity-Building Interventions on Malaria Case Management by Health Professionals in Uganda: A Mixed Design Study with Pre/Post and Cluster Randomized Trial C... by Martin Kayitale Mbonye (507318)

“…The proportion of patients with a negative diagnostic test result for malaria prescribed an antimalarial decreased in arm B (aRR = 0.96; 99%CI: 0.84, 1.10) and arm A (aRR = 0.67; 99%CI: 0.46, 0.97); (aRRR = 0.70; 99%CI: 0.48, 1.00). …”

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage by Toshio Watanabe (151136)

“…</p><p>Aim</p><p>We conducted a multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy of a high dose of rebamipide, a gastroprotective drug, for LDA-induced moderate-to-severe enteropathy.…”

Table_1_Associations among past trauma, post-displacement stressors, and mental health outcomes in Rohingya refugees in Bangladesh: A secondary cross-sectional analysis.pdf by Haley Ritsema (14431125)

“…Trauma (OR = 4.98, 95% CI = 2.20–11.31, p < 0.001) was associated with increased odds of PTSD. Living in a household that received income was associated with decreased odds of PTSD (OR = 0.74, 95% CI = 0.55–1.00, p = 0.05).…”

Table_1_Effectiveness of sofosbuvir-based treatments for patients with hepatitis C virus genotype 6 infection: a real-world study from East China.DOC by Fan-Rong Jiang (20325720)

“…In PP population, the end of treatment virological response rate was 99.48% (190/191), the SVR12 rate was 99.31% (143/144), and the SVR24 rate was 100.00% (75/75). Only one patient with genotype 6a experienced a relapse 12 weeks after the completion of treatment, but her HCV RNA was undetectable both at the end of treatment and 24 weeks after the end of treatment. …”

Data Sheet 1_Impact of mini-dose dexmedetomidine supplemented analgesia on sleep structure in patients at high risk of obstructive sleep apnea: a pilot trial.docx by Pei Sun (115160)

“…</p>Setting<p>A tertiary university hospital in Beijing, China.…”

Characterization of PEG-based hydrogels with cell adhesion peptides and impact of hydrogels on MVEC spreading and viability. by Rebecca A. Scott (488956)

“…White arrows point to tubule-like structures. Scale bar = 100 μm. In <b>B-C</b>: data are represented as the mean ± SEM, with <i>n</i> = 3 biological replicates per condition. …”